MRI Changes in MS — Treat Early to Reduce Relapses

Credibility

Interest

Share:2 min read

Key Takeaway

If a follow-up MRI shows new silent lesions in relapsing-remitting MS, changing to a stronger treatment soon can cut future relapses, though disability may still progress similarly over a few years.

What They Found

In people with relapsing-remitting MS, MRI scans sometimes show new “silent” lesions—spots of activity that do not cause symptoms but mean the disease is active. The study found those with silent lesions had a higher chance of having a relapse (a flare-up of symptoms) and a slightly higher chance of lasting disability over two years compared to people without such lesions. Even a single silent lesion raised the risk, not only when there were many. When doctors changed treatment to a stronger disease-modifying therapy within six months after seeing silent lesions, the chance of relapse over four years was much lower than when treatment was not changed. However, changing treatment did not clearly reduce the chance of disability getting worse over four years in this study.

Who Should Care and Why

People with relapsing-remitting MS should care because an MRI that looks normal in daily life can still show disease activity that raises future risk, like a warning light on a car dashboard. Caregivers should know that an MRI report with new silent lesions is information to discuss with the care team about treatment choices, not something to ignore. Neurologists and MS nurses may use this evidence to consider stepping up treatment sooner, similar to tightening safety measures when a small crack appears in a wall. Patients on milder or moderate treatments may benefit most from discussing treatment escalation after new silent lesions to lower relapse risk. This could affect daily life by reducing future relapses that can interrupt work, family time, or cause temporary disability.

Important Considerations

This study used real-world registry data, not a randomized trial, so other differences between people could affect the results even though the researchers adjusted for many factors. The benefit seen was mainly for lowering relapse risk; the study did not show clear reduction in long-term disability over four years, so patients should not expect the same effect on progression. Decisions about changing treatment should still be personalized, weighing side effects, monitoring needs, and personal goals with your healthcare team.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Diagnostics

Article Topics:

disease activityisolated MRI activityisolated radiological activitysilent MRI lesiontarget trial emulationtreatment strategy

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News